Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response
● Human Immune Cell Marker Guide: https://cst-science.com/rkkb1f
● Mouse Immune Cell Marker Guide: https://cst-science.com/q2r8ud
Participating Experts: Elizabeth M Jaffe MD, Johns Hopkins University, and Matthew Galsky MD, Mount Sinai
Tumors are complex hubs of cellular activity that incorporate immune cells, vasculature, and even bacteria. It has become increasingly clear that a better understanding of this tumor microenvironment and the different types of immune cells within it is critical to developing more effective cancer therapies. In particular, immunotherapies that target the signaling mechanisms of T cells have shown great promise for many patients. However, these techniques have proven successful for only a fraction of people and against just a few cancer types. A detailed dissection of the molecular signaling switches that control immune cell activation and tumor checkpoint evasion is required if we hope to broaden the reach of immunotherapy treatments. Our speakers describe key signaling mechanisms and shed light on how they can be utilized to better activate and control immune cells in the tumor microenvironment.
About CST:
About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about
All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks
#antibody
Видео Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response канала Cell Signaling Technology, Inc.
● Mouse Immune Cell Marker Guide: https://cst-science.com/q2r8ud
Participating Experts: Elizabeth M Jaffe MD, Johns Hopkins University, and Matthew Galsky MD, Mount Sinai
Tumors are complex hubs of cellular activity that incorporate immune cells, vasculature, and even bacteria. It has become increasingly clear that a better understanding of this tumor microenvironment and the different types of immune cells within it is critical to developing more effective cancer therapies. In particular, immunotherapies that target the signaling mechanisms of T cells have shown great promise for many patients. However, these techniques have proven successful for only a fraction of people and against just a few cancer types. A detailed dissection of the molecular signaling switches that control immune cell activation and tumor checkpoint evasion is required if we hope to broaden the reach of immunotherapy treatments. Our speakers describe key signaling mechanisms and shed light on how they can be utilized to better activate and control immune cells in the tumor microenvironment.
About CST:
About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about
All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks
#antibody
Видео Deciphering Immuno-Oncology: Targeting Cellular Mechanisms of the Tumor Immune Response канала Cell Signaling Technology, Inc.
Показать
Комментарии отсутствуют
Информация о видео
13 августа 2021 г. 23:24:44
01:02:29
Другие видео канала
Why Mariajose Chooses CST AntibodiesAccelerate Discoveries Up To 70% Faster with SignalStar™ Multiplex IHC | Cell Signaling TechnologyBioPlex: a Protein Interaction Network Created from Thousands of Protein ImmunopurificationsWhat Validation Steps Should You Expect From Your Antibody Manufacturer?Joan Brugge, Ph.D., Matrix Dependent Rewiring of Signaling Pathways Following Targeted TherapiesDo I Need to Do Additional Validation for Every Antibody That I Buy?The Study of Akt - Section 3 of 3.mp4Choosing a Lysis Buffer for Western Blot (WB) | CST Tech TipsThe Potential of Proteomics: A Clear Path to Discovery (Part 1)免疫組織化学染色 (IHC) の基礎:第5回 FAQJeffrey Settleman, Ph.D., The Many Flavors of Resistance To Anti-Cancer DrugsHistory of CSTA Day in the Life of a Product Scientist | Cell Signaling TechnologyVersatile Anti-Linker Antibodies for detection of CAR molecules from CST #shorts #biotechnologyウェスタンブロッティングの基礎:第3回 電気泳動・転写Proteomics Profiling of Post-Translational Modifications in Early Drug Discovery免疫蛍光染色の基礎:第3回 サンプル準備〜ブロッキングEpigenetic Analysis Using Highly Validated Antibodies and Optimized ChIP AssaysAsk these 3 Questions before your next immunofluorescence (IF) experiment第4回 ChIP以降の解析Customer Spotlight with Reuben Shaw, PhD – How CST Fuels Discovery